Hepatitis B Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and Virus Replication by Hösel, Marianna et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Hepatitis B Virus Activates Signal Transducer and Activator of
Transcription 3 Supporting Hepatocyte Survival and Virus Replication
Hösel, Marianna; Quasdorff, Maria; Ringelhan, Marc; Kashkar, Hamid; Debey-Pascher, Svenja; Sprinzl,
Martin F; Bockmann, Jan-Hendrik; Arzberger, Silke; Webb, Dennis; von Olshausen, Gesa; Weber,
Achim; Schultze, Joachim L; Büning, Hildegard; Heikenwalder, Mathias; Protzer, Ulrike
DOI: https://doi.org/10.1016/j.jcmgh.2017.07.003
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-144725
Published Version
 
 
Originally published at:
Hösel, Marianna; Quasdorff, Maria; Ringelhan, Marc; Kashkar, Hamid; Debey-Pascher, Svenja; Sprinzl,
Martin F; Bockmann, Jan-Hendrik; Arzberger, Silke; Webb, Dennis; von Olshausen, Gesa; Weber, Achim;
Schultze, Joachim L; Büning, Hildegard; Heikenwalder, Mathias; Protzer, Ulrike (2017). Hepatitis B
Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and
Virus Replication. Cellular and Molecular Gastroenterology and Hepatology, 4(3):339-363.
DOI: https://doi.org/10.1016/j.jcmgh.2017.07.003
ORIGINAL RESEARCH
Hepatitis B Virus Activates Signal Transducer and Activator
of Transcription 3 Supporting Hepatocyte Survival and
Virus Replication
Marianna Hösel,1,* Maria Quasdorff,1,2,* Marc Ringelhan,3,4 Hamid Kashkar,1,5
Svenja Debey-Pascher,6 Martin F. Sprinzl,3,7 Jan-Hendrik Bockmann,3,8 Silke Arzberger,1,3
Dennis Webb,1 Gesa von Olshausen,9 Achim Weber,10 Joachim L. Schultze,6
Hildegard Büning,1,8,11 Mathias Heikenwalder,3,8,12 and Ulrike Protzer3,8
1Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; 2Department of Gastroenterology and
Hepatology, University Hospital of Cologne, Cologne, Germany; 3Institute of Virology, Technische Universität München /
Helmholtz Zentrum München, Munich, Germany; 4Department of Internal Medicine II, University Hospital of the Technical
University of Munich, Munich, Germany; 5Institute of Medical Microbiology, Immunology and Hygiene, University Hospital of
Cologne, Cologne, Germany; 6Institute for Life and Medical Sciences, Genomics and Immunoregulation, University of Bonn,
Bonn, Germany; 71st Medical Department, University Hospital Mainz, Mainz, Germany; 8German Centre for Infection Research,
Partner sites Bonn-Cologne, Hannover-Braunschweig, Hamburg, and Munich, Germany; 9Department of Internal Medicine I,
University Hospital of the Technical University of Munich, Munich, Germany; 10Institute of Surgical Pathology, University
Hospital Zürich, Zürich, Switzerland; 11Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany;
12Department Chronic Inﬂammation and Cancer, German Cancer Research Center, Heidelberg, Germany
P
P
P
Acute phase
response
Apoptosis
HBV
Oxidative
stress
HCC
S
TA
T3
P
S
TA
T3
P cccDNA
STAT3 target gene
S
TA
T3
P
S
TA
T3
P
HNF4α
HBV RNA
replication
STAT3
STAT3
STAT3
STAT3
SUMMARY
We show that hepatitis B virus infection activates STAT3
signaling that supports virus replication and prevents
apoptosis of infected hepatocytes potentially supporting
malignant transformation. Our ﬁndings provide new insides
into hepatitis B virus–host interaction and open a new
avenue to the development of drugs that control the
infection and may help to prevent carcinoma development.
BACKGROUND & AIMS: The human hepatitis B virus (HBV) is
a major cause of chronic hepatitis and hepatocellular carci-
noma, but molecular mechanisms driving liver disease and
carcinogenesis are largely unknown. We therefore studied
cellular pathways altered by HBV infection.
METHODS:We performed gene expression proﬁling of primary
human hepatocytes infected with HBV and proved the results in
HBV-replicating cell lines and human liver tissue using real-
time polymerase chain reaction and Western blotting. Activa-
tion of signal transducer and activator of transcription (STAT3)
was examined in HBV-replicating human hepatocytes, HBV-
replicating mice, and liver tissue from HBV-infected
individuals using Western blotting, STAT3-luciferase reporter
assay, and immunohistochemistry. The consequences of STAT3
activation on HBV infection and cell survival were studied by
chemical inhibition of STAT3 phosphorylation and small
interfering RNA–mediated knockdown of STAT3.
RESULTS: Gene expression proﬁling of HBV-infected primary
human hepatocytes detected no interferon response, while
genes encoding for acute phase and antiapoptotic proteins
were up-regulated. This gene regulation was conﬁrmed in liver
tissue samples of patients with chronic HBV infection and in
HBV-related hepatocellular carcinoma. Pathway analysis
revealed activation of STAT3 to be the major regulator.
Interleukin-6–dependent and –independent activation of
STAT3 was detected in HBV-replicating hepatocytes in cell
culture and in vivo. Prevention of STAT3 activation by inhibi-
tion of Janus tyrosine kinases as well as small interfering
RNA–mediated knockdown of STAT3-induced apoptosis and
reduced HBV replication and gene expression.
CONCLUSIONS: HBV activates STAT3 signaling in hepatocytes
to foster its own replication but also to prevent apoptosis of
infected cells. This very likely supports HBV-related carcino-
genesis. (Cell Mol Gastroenterol Hepatol 2017;4:339–363; http://
dx.doi.org/10.1016/j.jcmgh.2017.07.003)
Keywords: Hepatitis B Virus Infection; STAT3 Signaling;
Hepatocellular Carcinoma; Apoptosis.
The hepatitis B virus (HBV) is a small, enveloped DNAvirus characterized by a pronounced liver tropism
and replication via reverse transcription (RT) of an RNA
pregenome. Despite an effective prophylactic vaccine, HBV
infection still is a major health problem, with more than 240
million chronically infected individuals, who are at high risk
to develop liver cirrhosis, end-stage liver disease and
hepatocellular carcinoma (HCC). The virus escapes efﬁcient
immune elimination by a very limited activation of innate
and adaptive immune responses in the liver.1 With the
introduction of antivirals, treatment options for chronic
hepatitis B improved over the last years, but a curative
treatment is still lacking.2 Although rates of HBV-related
HCC are slowly decreasing,3 HCC still rates number 6
among the most frequent cancers and is the number 3 cause
of cancer-related death with about half of all HCC related to
HBV infection.4 Advanced liver disease with liver cirrhosis
due to ongoing hepatocellular activation and inﬂammation
are major risk factors.5,6 Persistent viral replication, male
sex and a positive family history increase the risk for
HBV-related HCC.6
A strong correlation between HBV viral load and the risk
of HCC development has been established in large clinical
trials.5 In the absence of a dominant oncogene encoded by
the HBV genome, the role of HBV in carcinogenesis is
complex7 and still incompletely understood. Direct as well
as indirect roles of HBV have been proposed.8 Integration of
HBV DNA into the host genome occurs at early steps of
clonal tumor expansion. This may activate cellular
cancer-related genes and very likely induces the host
chromosomal instability. Hereby, prolonged expression of
the viral regulatory HBV X protein may contribute to de-
regulating cellular transcription and inﬂuences protein
degradation, cell proliferation and apoptotic signaling
pathways (summarized in Neuveut et al,8 Ringelhan et al,9
and Tan10).
In a number of clinical settings and disease entities
chronic liver inﬂammation seems to be sufﬁcient to induce
HCC development.11 Pioneering work by Nakamoto et al12
provided ﬁrst experimental evidence that HBV-related
HCC may develop in the absence of viral transactivation,
insertional mutagenesis, and genotoxic chemicals12 solely
triggered by the immune response to HBV and resulting
chronic inﬂammation. Key signaling pathways contributing
to HCC development, however, have only partially been
identiﬁed.
Lymphotoxins (LTs) and their receptor are up-regulated
in viral hepatitis and related HCC, and sustained triggering
of the LT-beta receptor resulting in canonical and nonca-
nonical NF-kb signaling leads to HCC development.13 We
have previously demonstrated that nonparenchymal liver
cells, particularly liver macrophages, recognize HBV parti-
cles resulting in an activation of NF-kb signaling and pro-
duction of proinﬂammatory cytokines (eg, tumor necrosis
factor-a, interleukin 6 [IL-6]).14 IL-6 induces signal trans-
ducer and activator of transcription (STAT3) signaling in
hepatocytes, and NF-kB and STAT3 have been described to
be key players in liver inﬂammation and cancer (reviewed
in He and Karin15).
In this study, we aimed at identifying major signaling
pathways activated by HBV infection in hepatocytes. As
signaling cascades may be largely affected in immortalized
cell lines as well as by overexpression of viral proteins, we
studied the inﬂuence of HBV replication on cellular gene
expression in infected primary human liver cell cultures
prepared from different donors and in human liver tissues
derived from patients with chronic hepatitis B and HBV-
related HCC. Finally, we corroborated our ﬁndings in
transgenic mice expressing the complete genome of HBV in
hepatocytes16 and in mice challenged intravenously with
adenoviral vectors encoding a replication competent HBV
genome (Ad HBV).17–19
Methods
Chemicals
The pharmacological inhibitor AG-490 was purchased
from Calbiochem (San Diego, CA). Dimethyl sulfoxide
(DMSO) and N-acetyl-L-cysteine (NAC) were obtained from
Sigma (St. Louis, MO).
Ethics Statement
The study followed the ethical guidelines of the Decla-
ration of Helsinki and use of human material was approved
by the local ethics committees of the University Hospital
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Cologne, the University of Zürich, and the Hospital rechts
der Isar der Technischen Universität München. Liver cell
cultures were prepared from surgical human liver biopsies
after written informed consent of patients. Studies on mice
were conducted in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (USA). Our animal protocol was
approved by the Regierung Oberbayern (Munich, Germany).
Patients
Samples of HBV-positive tumor tissue or noncancerous
HBV-infected liver tissue were recruited from the tissue
bank of the Institute of Pathology, University of Cologne, and
the Institute of Surgical Pathology, University Hospital
Zürich, after obtaining written informed consent from all
patients. All tissue samples stained positive for hepatitis B
core antigen and hepatitis B surface antigen. Active HBV
replication in all noncancerous HBV-infected liver tissue
samples was conﬁrmed by the detection of pregenomic RNA
(pgRNA) using real-time RT polymerase chain reaction
(PCR). All tumor samples were HBV-related HCC with
Edmonson’s grade II or III of histological differentiation,
whereas other causative agents for HCC were excluded.
Noninfected (HBV negative, hepatitis C virus negative,
human immunodeﬁciency virus negative) liver tissue was
obtained from human liver grafts not suited for
transplantation.
Infection of Primary Human Hepatocytes With
HBV and Analysis of Infection
Primary human hepatocyte (PHH) cultures were pre-
pared from surgical human liver biopsies after written
informed consent of patients by a standard 2-step collage-
nase perfusion followed by a differential centrifugation as
described previously.20 PHH cultures contained 85% he-
patocytes and 3%–15% of liver sinusoidal endothelial cells
or liver macrophages, Kupffer cells.14 HBV inoculum was
concentrated from the medium of HepG2.2.15 cells21 using
centrifugal ﬁlter devices (Centricon Plus-70, Biomax
100.000, Millipore Corp, Bedford, MA) and sedimented into
a CsCl gradient to determine the amount of enveloped,
DNA-containing viral particles as described before.22 Mock
inoculum was concentrated from HepG2 cells accordingly.
On day 3 after seedling, PHHs were infected with HBV at a
multiplicity of infection of 250 enveloped DNA-containing
viral particles per cell in the presence of 5% PEG 6000. At
24 hours after infection with HBV, the inoculum was
removed, and cells were cultivated in PHH medium23 at
37C in 5% CO2 for next 4 days.
Cell culture medium was collected from day 1 to day 4
postinfection (p.i.), and hepatitis B early antigen (HBeAg)
secretion was determined using the HBeAg 2.0 Axsym
immuno assay (Abbott Laboratories, Wiesbaden, Germany).
In addition, IL-6 secretion was determined using IL-6
enzyme-linked immunosorbent assay (ELISA) (BD Bio-
sciences, Heidelberg, Germany) and IFNa production was
examined using interferon-a (IFNa) ELISA (PBL Biomedical
Laboratories Piscataway, NJ).
Formation of HBV covalently closed circular DNA
(cccDNA) was detected by real-time PCR on a LightCycler
instrument (Roche Diagnostics, Mannheim, Germany) using
speciﬁc primers ccc2760fw and HBVccc156rev selectively
amplifying cccDNA over relaxed circular DNA as described
previously.24 Total DNA extracted from mock- (control) or
HBV-infected PHHs was subjected to real-time PCR analysis
to speciﬁcally detect HBV cccDNA. DNA extracted from pa-
tient serum and from serum of an HBV-positive chimpanzee
as well as total liver DNA extracted from HBV-positive pa-
tient served as negative and positive controls, respectively.
To estimate relative efﬁciency of HBV replication in
PHHs, levels of HBV pgRNA were determined relative to
those in PHH transduced with AdG-HBV1.3 vector24 using
RT-PCR and pgRNA speciﬁc primers.23 After infection with
AdG-HBV1.3, an adenoviral vector containing a linear
1.3-fold over length HBV genome and a green ﬂuorescent
protein expression cassette,24 at an multiplicity of infection
of 1–2 infectious units per cell, virtually all hepatocytes
were infected. The pgRNA levels were here deﬁned as
100%.
Animals
HBV transgenic (HBVtg) C57BL/6J mice carrying a
replication competent 1.3-fold HBV genome16 were exam-
ined in comparison to wild type C57BL/6J mice. In addition,
C57BL/6J mice were infected with adenovirus type 5
vectors transferring an HBV genome (Ad HBV) or as control
with an identical construct in which all open reading frames
were knocked out by introducing stop codons (Ad HBV/
ko).19 All animals received humane care equivalent to the
“Guide for the Care and Use of Laboratory Animals”
prepared by the U.S. Academy of Sciences and published by
the National Institutes of Health.
Cell Culture
HepG2 cells (ATCC number: HB-8065), HBV-replicating
HepG2.2.15,21 or HepG2-H1.3 cells25 were plated onto
dishes coated with collagen type IV (Serva Electrophoresis,
Heidelberg, Germany) and cultivated in Dulbecco’s modiﬁed
Eagle medium containing 10% (w/v) fetal calf serum (FCS)
as described.23 After achieving 80%–90% conﬂuence, cell
cultures were maintained in the Williams E / Dulbecco’s
modiﬁed Eagle medium (1:1, v/v) containing 5% FCS.
HepaRG cells were differentiated and infected with HBV as
described previously.23 Cell viability upon treatment with
AG-490 was analyzed by CellTiter-Blue Cell Viability Assay
(Promega, Madison WI).
RNA Isolation, Microarray Procedure and
Data Analysis
Total RNA from mock- or HBV-infected cells was isolated
with Trizol reagent (Invitrogen/Thermo Fisher Scientiﬁc,
Waltham, MA) and cleaned up using RNeasy mini kit
including DNAse digestion (Qiagen, Hilden, Germany).
A total of 100 ng of total RNA was used to generate
double-stranded complementary DNA (cDNA) with a
T7(dT)24-oligonucleotide primer performed with the Two
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Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA) fol-
lowed by an in vitro transcription reaction to amplify the
cDNA using the MEGAScript T7 Kit (Ambion, Kaufungen,
Germany). After puriﬁcation with the Sample Cleanup
Module, cRNA served as a template to prepare a second
round of cDNA. After puriﬁcation of the cDNA with the
sample Cleanup Module, biotinylated cRNA was generated,
using the GeneChip IVT Labeling Kit (all reagents from
Affymetrix). Hybridization of complementary RNA (cRNA)
to the high-density oligonucleotide microarrays (HG-U133A
arrays; Affymetrix) was performed according to the manu-
facturer’s GeneChip Expression Analysis Technical Manual.
For data collection, assessment and analysis we used
Affymetrix Microarray Analysis Suite Version 5.0 program
(MAS5.0). Transcripts were considered to be up-regulated,
when the absolute call in HBV sample was not absent, and
the difference call was increased or marginal increased
and fold change in gene expression between HBV–infected
and appropriate mock samples was 1.5. Transcripts were
considered as down-regulated, when the absolute call of the
mock control was not “absent,” the difference call was
decreased or marginal decreased, and fold change in gene
expression was 1.5.
Quantiﬁcation of Gene Expression by Real-Time
LightCycler PCR
Total RNA (650 ng) isolated from PHHs or hepatoma
cells as described previously was reverse transcribed into
cDNA using the Superscript III First-Strand Synthesis Sys-
tem (Invitrogen/Thermo Fisher Scientiﬁc). Real-time PCRs
were performed with the LightCycler FastStart DNA
MasterPLUS SYBR Green Kit using the LightCycler system and
normalized to a dilution series of calibrator cDNA using the
Relative Quantiﬁcation Software (all Roche Diagnostics) as
described.14,25 Primers for target genes were chosen with
the assistance of LightCycler primer design program (Roche
Diagnostics) and listed in Table 1. Primers for the reference
genes glyceraldehyde-3-phosphate dehydrogenase and 5-
aminolevulinate synthase, for hepatocyte nuclear factor 4
alpha (HNF4a), hepatocyte nuclear factors 3 alpha and beta
(HNF3a and HNF3b, respectively) were published
earlier.14,23 For expression analysis of selected genes in
HBV-expressing liver tumor and nontumorous tissue and in
the healthy liver, 1 mg of total RNA was reverse transcribed
into cDNA and applied for real-time PCR and as described
previously. cDNA levels were normalized for the expression
of the ALAS1 gene.
Western Blot Analysis
Nuclear and cytoplasmic protein extracts from mock- or
HBV-infected cells were isolated with NE-PER Nuclear and
Cytoplasmic extraction Reagents (Pierce/Thermo Fisher
Scientiﬁc). Purity of nuclear protein preparations was
controlled by Western blotting using antialbumin anti-
bodies. Total proteins were extracted with CHAPS buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 1% Chaps) containing
phosphatase inhibitors sodium vadanate and sodium
ﬂuoride.
Proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and analyzed by Western
blotting as described.23 The following primary antibodies
were used: mouse monoclonal anti-cIAP2 and mouse mono-
clonal anti–poly(ADP-ribose) polymerase (BD Biosciences,
San Diego, CA); mouse monoclonal anti-Phospho-STAT3-
Tyr705, rabbit monoclonal anti-STAT3, rabbit monoclonal
anti-Src and rabbit polyclonal anti-Phospho-src family
(Tyr416) (Cell Signaling, Denvers,MA); rabbit polyclonal anti-
Mn-SOD, rabbit polyclonal anti–interferon regulatory factor 3
(IRF3), rabbit polyclonal anti-lamin B1, and rabbit polyclonal
antialbumin (Santa Cruz Biotechnology, Santa Cruz, CA);
mousemonoclonal anti-b actin (Sigma); and rabbit polyclonal
anti-HBV core.23,26 The secondary antibodies were anti-
mouse or anti-rabbit IgG horseradish peroxidase–coupled
antibodies (Sigma). ImageJ software, version 1.51h (National
Institutes of Health, Bethesda, MD) was applied for densito-
metric quantiﬁcation of Western blot signals.
Immunohistochemistry
Fixed, pretreated 2-mm-thick, parafﬁn-embedded liver
sections derived from human liver needle biopsies or from
mouse liver tissue were decorated with a monoclonal anti-
body against phosphor-Stat3 (Tyr 705). The antibody was
Table 1.Primer Sets Used for LightCycler Real-Time PCR
Gene LightCycler PCR Primers
cIAP2 fw: 50-TGAAGCTGTGTTATATGAGCA-30
rev: 50-ACGAACTGTACCCTTGAT-30
Mn-SOD fw: 50-AGCCCAGATAGCTCTTC-30
rev: 50-AGGTAGTAAGCGTGCTC-30
TNFAIP8 fw: 50-GCTTGCTTAGGGCTTC-30
rev: 50-GCTCATGTTCTTTAGCAGT-30
IER3 fw: 50-CGAGGCGCATAGAGAC-30
rev: 50-CTACTTTGCCGCAGTTC-30
IGFBP1 fw: 50-AGAGCACGGAGATAACT-30
rev: 50-TCCAAGGGTAGACGCA-30
CRP fw: 50-ACATTCACAGGGCTCT-30
rev: 50-ACAAGGTTCGTGTGGA-30
CCL2 fw: 50-AGATGCAATCAATGCCC-30
rev: 50-GTTGTGGAGTGAGTGTTC-30
IL-8 fw: 50-AAGAACTTAGATGTCAGTGC-30
rev: 50-ACTTCTCCACAACCCT-30
APOE fw 1: 50-CAAGGTGGAGCAAGCG-30
rev 1: 50-ATGGTCTCGTCCATCAG-30
CYP3A4 fw: 50-TCACCGTGACCCAAAG-30
rev: 50-TTTGAGGTCTCTGGTGT-30
2‘5’OAS fw: 50-CAGTTAAATCGCCGGG-30
rev: 50-AGGTTATAGCCGCCAG-30
IP10 fw: 50-ACTGTACGCTGTACCT-30
rev: 50-TGGCCTTCGATTCTGGA-30
IL-6 fw: 50-AAACAACCTGAACCTTCC-30
rev: 50-CAGGGGTGGTTATTGC-30
STAT3 fw: 50-TTCGGAAAGTATTGTCGGC-30
rev: 50-GGGTTTGGCTGTGTGA-30
NOTE. PCR, polymerase chain reaction.
342 Hösel et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 3
purchased from Cell Signaling (clone #D3A7, dilution 1:100).
Pretreatment (H2(60)) and staining were performed on a
Leica Bond-Max, detection with a Bond Polymer reﬁne kit
(Leica Biosystems, Heidelberg, Germany) using an anti-rabbit
secondary antibody, coupled to horseradish peroxidase and
3,3’-diaminobenzidine as a substrate. Stainings were
analyzed and pictures were taken with an Olympus BX53 and
an Olympus DP72 camera (Olympus, Tokyo, Japan).
Detection of STAT3 Activation
To detect phosphor STAT3-Y705, total or nuclear protein
extracts were analyzed by Western blotting using mouse
monoclonal anti-Phospho-STAT3-Tyr705 antibodies (Cell
Signaling) as described previously. To additionally measure
STAT3 activity in cells, the Cignal STAT3 Reporter (luc)
Assay (Qiagen) was applied. To this end, HepG2 or HepG2-
H1.3 cells were transfected with either Cignal reporter or
positive or negative control constructs using the fast-
forward protocol provided by the manufacturer. The
activity of STAT3-dependent Fireﬂy luciferase and the ac-
tivity of constitutively expressed Renilla luciferase used for
internal normalization were measured by the Dual-
Luciferase Reporter Assay System (Promega) according to
manufacturer’s instructions.
Detection of Reactive Oxygen Species
HepG2, HepG2.2.15, or HepG2-H1.3 cells were plated on
collagen-coated 96-dishes to reach conﬂuence (day 1) and
maintained in Williams E or Dulbecco’s modiﬁed Eagle
medium (1:1, v/v) containing 1% FCS. HepaRG cells were
plated on collagen-coated 96-dishes, differentiated and
HBV- or mock-infected. Reactive oxygen species were
measured using Cellular Reactive Oxygen Species Detection
Assay Kit (Abcam, Cambridge, UK) according to manufac-
turer’s instructions. This assay measures hydroxyl, peroxyl,
and other reactive oxygen species (ROS) activity within the
cell. Speciﬁcally, HepG2, HepG2-2.15, HepG2-H1.3, and
noninfected or HBV-infected HepaRG cells (1  104 cells per
probe) were harvested by trypsinization and subsequently
stained with 20 mM DCFDA in cell culture medium for 30
min followed by ﬂow cytometry assay. To analyze the in-
ﬂuence of ROS inhibition on STAT3 activity, HepG2 or
HepG2-H1.3 cells were ﬁrst transfected with either the
cignal reporter- or positive- or negative control constructs
(Qiagen) using the STAT3-luciferase reporter assay by the
fast-forward protocol according to manufacturer’s in-
structions. 18 hours later, cell culture medium was changed
and 5 mM ROS-inhibitor NAC was added to the culture
medium of HepG2-H1.3 cells. Then, 48 hours thereafter, the
activity of STAT3-dependent Fireﬂy luciferase and the ac-
tivity of constitutively expressed Renilla luciferase used for
internal normalization were measured by the Dual-
Luciferase Reporter Assay System (Promega) according to
manufacturer’s instructions.
Small Interfering RNA Knockdown
HepG2-H1.3 cells were transfected with 5 nM of either
STAT3-speciﬁc small interfering RNA (siRNA) (Hs_STAT3_7
FlexiTube siRNA, functionally veriﬁed siRNA directed
against human STAT3; NM_003150, NM_139276,
NM_213662) or nonsilencing siRNA using the HiPerFect
transfection reagent (both from Qiagen) according to the
fast-forward protocol provided by manufacturer. The
knockdown of STAT3 was conﬁrmed at the messenger RNA
(mRNA) and protein level by real-time RT-PCR and Western
blot analysis, respectively.
Caspase 3/7 Assay
The activity of 2 effector caspases, caspase-3 and
caspase-7 (caspase 3/7), was measured by luminescent
Caspase-Glo 3/7 assay (Promega). PHHs were seeded at a
density of 4  105 cells per well in a 24-well culture plates.
PHHs were treated with 100 mM of AG-490 or with 0.1%
DMSO for 24 hours, and then lysed in 200 mL of cell culture
lysis buffer (Promega). The luminescence was measured
after addition of the caspase 3/7 substrate according to the
manufacturer’s instructions.
Statistics
Statistical signiﬁcance was determined by Student’s un-
paired 2-tailed t test. Differences with P  .05 were
considered statistically signiﬁcant.
Results
HBV Induces Up-Regulation of Genes Encoding
Acute Phase Response Proteins and Proteins
Promoting Cell Survival
PHH cultures were prepared from 7 patients under-
going surgical liver resection and were either mock- or
HBV-infected in parallel experiments. To monitor HBV
infection, cell lysates and culture medium were collected
daily from day 1 to day 4 p.i. On day 4 p.i., we detected the
formation of HBV cccDNA by a selective, quantitative
real-time PCR24 and the release of newly synthesized
HBeAg into the cell culture medium of HBV-infected PHHs
(Figure 1A and B, respectively) conﬁrming successful HBV
infection. To compare efﬁciency of HBV infection in
different PHH cultures, total cellular RNA was extracted
on day 4 p.i., and levels of HBV pgRNA were determined
relative to those in PHHs transduced with AdG-HBV1.3
vector (Figure 1C) using quantitative real-time RT-PCR
and pgRNA speciﬁc primers as described in the Methods.
The efﬁciency of infection with HBV broadly varied
between 5% and 45%. Three experiments, in which
infection rates were 15%, named PHH1, PHH2, and
PHH3 (Table 2), were selected for gene expression
analysis.
To detect changes in cellular gene expression and acti-
vation of appropriate cellular pathways at the beginning of
productive HBV infection, we harvested HBV and mock
infected PHHs on day 4 p.i., when HBV replication in
infected cells had just started as indicated by the detection
of newly synthesized HBeAg after formation of cccDNA
(Figure 1A and B). We chose this time point to ensure HBV
replication and to determine the inﬂuence of HBV
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replication on hepatocytes, but avoid inﬂuences or early
pattern recognition of the HBV inoculum14 as well as
dedifferentiation of the primary cells at later time points.
cRNAs derived from mock- and HBV-infected samples were
hybridized to HG-U133A Affymetrix oligonucleotide micro-
array containing 22,283 probe sets representing approxi-
mately 14,000 human genes.
The total number of transcripts regulated 1.5-fold
upon HBV infection was relatively low, and correlated
with the efﬁciency of infection. Comparative analysis of 3
HBV infection experiments detected 40 genes up-regulated
and 17 genes down-regulated in all 3 experiments
(Table 2). This minor overlap reﬂects the variability be-
tween primary hepatocytes prepared from different donors
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but also the high adaptation of HBV to the host cell envi-
ronment. At the same time, it shows that HBV infection and
HBV replication inﬂuence the host cell gene expression
proﬁle—even if only at a low level.
Based on results obtained from microarray analyses, we
grouped genes with altered expression patterns according
to their biological functions (Table 3). The largest group of
genes, up-regulated upon HBV infection promoted cellular
acute phase response (APR). Among them, C-reactive pro-
tein (CRP) was induced most strongly upon HBV infection.
In contrast, several cellular genes implicated in lipid and
xenobiotic metabolism as well as cytochrome P 450
(CYP450) family members involved in biotransformation
and generation of ROS27 were down-regulated in HBV-
infected hepatocytes.
A divergent regulation was identiﬁed for genes associ-
ated with apoptosis induction and cell survival. Importantly,
in the 2 experiments with the highest efﬁciency of HBV
infection (PHH2 and PHH3), 4 established apoptosis inhib-
itor genes: cIAP2 (apoptosis inhibitor 2),28,29 IER3 (imme-
diate early response protein 3),30 TNFAIP 8 (tumor necrosis
factor-a–induced protein 8),31 and IGFBP1 (insulin-like
growth factor binding protein 1)32 (Table 3) were up-
regulated. In addition, genes encoding for PBEF1 (pre–
B-cell colony enhancing factor 1),33 IL-8,34 Mn-SOD
(manganese superoxide dismutase),35,36 CCL2 (Chemokine
[C-C motif] ligand 2 / monocyte chemoattractant protein-
1),37 and CRP38 with reported antiapoptotic activities, were
markedly up-regulated in all experiments (Table 3).
To conﬁrm regulation of gene expression by real-time
RT-PCR, PHH4 and PHH5 with HBV infection rates 36%
and 29%, respectively, were additionally used. RNA
expression levels for the 10 highest regulated genes from
APR, antiapoptosis, and CYP450 groups were determined in
PHH2, PHH3, PHH4, and PHH5 with and without HBV
infection (Table 4). Real-time RT-PCR conﬁrmed the regu-
lation of all genes. Most importantly, the fold change of gene
expression detected by real time RT-PCR was very compa-
rable to that identiﬁed by microarray analysis (Tables 3
and 4).
Next, we aimed at verifying alterations in HBV-infected
PHH4 and PHH5 at the protein level. Western blot ana-
lyses for representative proteins cIAP2 and Mn-SOD
conﬁrmed their up-regulation in HBV-infected PHHs
compared to respective mock controls (Figure 1D). As the
microarray analysis did not reveal activation of any genes
involved in a type I or II IFN response, we additionally
examined expression levels of IFN type I-inducible
2’5’-oligoadenylatsynthetase and IFN-inducible protein 10
(IP10) genes. For both, real time RT-PCR analysis revealed
Table 2.Gene Expression Proﬁling of HBV-Infected PHH Cultures
Samplea
Transcripts
up-regulatedb
Transcripts
down-regulatedb
Relative efﬁciency of
HBV replication (%)c
HBeAg
(ng/mL)d
PHH1 192 416 15 11.1
PHH2 894 1364 45 21.7
PHH3 511 349 30 14.95
Common regulated in all PHHs 40 17 — —
aPrimary human hepatocyte (PHH) prepared from different patients (1–3), RNA isolated on day 4 post–mock or hepatitis B virus
(HBV) infection.
bUp- or down-regulated transcripts in HBV-infected PHHs compared with mock-infected PHH, fold change 1.5.
cRelative expression levels of HBV pregenomic RNA determined by real-time reverse transcription polymerase chain reaction
on day 4 postinfection.
dLevels of hepatitis B early antigen secreted into the culture medium on day 4 postinfection.
Figure 1. (See previous page). Up-regulation of apoptosis inhibitors induced by hepatitis B virus (HBV) replication in
primary human hepatocyte (PHHs). (A) Formation of HBV covalently closed circular DNA (cccDNA) in HBV-infected PHHs
was examined by real-time polymerase chain reaction (PCR) using total DNA extracted from mock- (control) or HBV-infected
PHH cultures on day 4 postinjection (p.i.). DNA extracted from high-titer (>5  10e8/mL) serum of an HBV-positive patient and
from serum of an HBV-positive chimpanzee containing HBV relaxed circular DNA were used as speciﬁcity (negative) controls.
Total liver DNA extracted from HBV-positive patient and plasmid DNA encoding for HBV 1.3-overlength genome served as
positive controls. PCR products were separated in a 2% agarose gel, water control, and DNA size marker (M) are indicated. (B)
Hepatitis B early antigen (HBeAg) was measures in cell culture supernatants from day 1 to 4 p.i. of HBV-infected PHHs
prepared from 2 different donors (PHH4 and PHH5) as signal-to-control ratio. Day 1 values reﬂect input virus. Values are
shown as mean ± SD (n ¼ 3; ***P < .001; Student’s t test). (C) PHH cultures were infected with AdG-HBV1.3 at a multiplicity of
infection of 1–2 infectious units per cell. Expression of green ﬂuorescent protein was visualized by ﬂuorescence microscopy at
24 hours p.i. (D) Expression of cIAP2, Mn-SOD, and b-actin (loading control) in mock- or HBV-infected PHH4 and PHH5 was
analyzed by Western blot analysis of total protein extracts prepared on day 4 p.i. Levels of interferon regulatory factor 3 (IRF3)
and lamin (loading control) in the nucleus of mock- or HBV-infected PHH4 and PHH5 were determined by Western blot
analysis of nuclear proteins extracted on day 4 p.i. (left panel). Densitometric quantiﬁcation (right panel) of cIAP2 or Mn-SOD
relative to b-actin and interferon regulatory factor 3 (IRF3) relative to lamin was performed using ImageJ software. Protein
levels are given relative to respective mock control (set to 1).
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Table 3.Functional Grouping of Genes Identiﬁed by Affymetrix Analyses
Functional relevance
of regulated genes Gene Description Public ID
Fold changea
PHH1b PHH2b PHH3b
Positive APR
Major APR CRPc C-reactive protein, pentraxin-related NM_000567 9.2 I 45 I 512 I
SAA1 Serum amyloid 1 NM_000331 2 I 4.3 I 2.5 I
SAA2 Serum amyloid 2 NM_030754 2.3 I 11.3 I 3 I
APCS Amyloid P component, serum NM_001639 2 I 2.5 I 1.6 I
Coagulation proteins FGA Fibrinogen alpha chain NM_000508 2.6 I 7.5 I 4.6 I
FGB Fibrinogen beta chain NM_005141 1.6 I 2.1 I 1.7 I
FGG Fibrinogen gamma chain NM_000509 1.7 I 2.3 I 1.6 I
FGL-1 Fibrinogen-like protein NM_004467 2.3 I 2.5 I 2.5 I
Metal-binding proteins HP Haptoglobin NM_005143 1.9 I 1.7 I 2 I
HPR Haptoglobin-related protein NM_020995 2.6 I 1.7 I 2.3 I
Mn-SODc Superoxide dismutase 2, mitochondrial NM_000636 2 I 3.7 I 4.3 I
Proteinase inhibitors SERPINA 1 Serpin peptidase inhibitor, clade A, member 1, anti-trypsin NM_000295 1.8 I 1.4 I 1.9 I
SERPINA 3 Serpin peptidase inhibitor, clade A, member 3, anti-trypsin NM_001085 2.1 I 2.2 I 2 I
Complement proteins C4A Complement component 4A NM_007293 2.8 I nc 3 I
C9 Complement component 9 NM_001737 3.2 I 3.7 I 16 I
Other proteins LBP Lipopolysaccharide-binding protein NM_004139 4.3 I 8 I 9.2 I
ORM1 Orosomucoid 1 NM_000607 2.7 I 2.3 I 3.2 I
ORM2 Orosomucoid 2 NM_000608 2.3 I 1.8 I 5.3 I
Negative APR ALB Albumin NM_000477 nc –2.5 D –1.6 D
ITIH2 Interalpha (globulin) inhibitor H2 NM_002216 nc –2 D –2.5 D
HRG Histidine-rich protein NM_000412 nc –6.1 D –1.5 D
Chemokines CXCL1 Chemokine (C-X-C motif) ligand 1 NM_001511 2.9 I 15.3 I 33 I
CXCL2 Chemokine (C-X-C motif) ligand 2 NM_002089 1.5 I 82 I 8 I
CXCL5 Chemokine (C-X-C motif) ligand 5 NM_002994 nc 9.2 I 7 I
CXCL6 Chemokine (C-X-C motif) ligand 6 NM_002993 1.7 I 13.3 I 29 I
CCL2c Chemokine (C-C motif) ligand 2 NM_002982 5.9 I 11.9 I 19.3 I
CCL20 Chemokine (C-C motif) ligand 20 NM_004591 1.7 I 26.7 I 6.7 I
Apoptosis
Negative regulators cIAP2 cIAP2 apoptosis inhibitor 2, Birc3 NM_001165 nc 4.9 I 4.6 I
IER3 Immediate early response 3 NM_003897 nc 4.4 I 1.9 I
TNFAIP8 Tumor necrosis factor-a–induced protein 8, FLIP-like, SCC-S2 NM_014350 nc 2.5 I 2.3 I
Mn-SOD Superoxide dismutase 2, mitochondrial NM_000636 2 I 3.7 I 4.3 I
PBEF1 Pre–B-cell colony enhancing factor 1 NM_005746 nc 2.3 I 3.3 I
CRP C-reactive protein, pentraxin-related NM_000567 9.2 I 45 I 512 I
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Table 3.Continued
Functional relevance
of regulated genes Gene Description Public ID
Fold changea
PHH1b PHH2b PHH3b
IL-8 Interleukin 8 NM_000584 nc 21 I 8 I
CCL2 Chemokine (C-C motif) ligand 2 NM_002982 5.9 I 11.9 I 19.3 I
IGFBP1 Insulin-like growth factor binding protein 1 NM_000596 nc 113.8 I 4.3 I
Positive regulators APOEc Apolipoprotein E NM_000041 nc –10.5 D –2.7 D
CASP4 Caspase 4 NM_001225 nc 3.6 I 1.8 I
Metabolism
Antioxidant proteins Mn-SOD Superoxide dismutase 2, mitochondrial NM_000636 2 I 3.7 I 3.7 I
GPX2 Glutathione peroxidase 2 NM_002083 5.1 I 3.1 I 6.1 I
CP Ceruloplasmin (ferroxidase) NM_000096 nc 4.8 I 7 I
Xenobiotic metabolism proteins CYP3A4c Cytochrome P450, Family 3, subfamily A, polypeptide 4 NM_000776 –2.8 D –6.5 D –7 D
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15 NM_001076 –2.3 D –16 D –13 D
UGT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 NM_053039 nc –6.4 D –2.5 D
Oxydoreductases and electron transport proteins CYP3A4 Cytochrome P450, Family 3, subfamily A, polypeptide 4 NM_000776 –2.8 D –6.5 D –7 D
CYP3A7 Cytochrome P450, Family 3, subfamily A, polypeptide 7 NM_000765 –1.6 D –2.5 D –2 D
CYP2C8 Cytochrome P450, Family 2, subfamily C, polypeptide 8 NM_030878 –1.6 D –8 D –4.4 D
CYP2A6 Cytochrome P450, Family 2, subfamily A, polypeptide 6 NM_000762 nc –4.9 D –6.1 D
CYP2C9 Cytochrome P450, Family 2, subfamily C, polypeptide 9 NM_000771 –2 D –3.5 D –5.7 D
CYP2C19 Cytochrome P450, Family 2, subfamily C, polypeptide 19 NM_000769 –1.7 D –5.3 D –1.9 D
GRHPR Glyoxylate reductase, hydroxypyruvate reductase NM_012203 nc –2.5 D –2.8 D
ACADL Acyl-coenzyme A dehydrogenase, long chain NM_001608 –1.7 D –2.6 D –2 D
BDH 3-hydroxybutyrate dehydrogenase NM_004051 nc –1.9 D –5.5 D
Lipid metabolism and transport proteins APOE Apolipoprotein E NM_000041 nc –10.5 D –2.7 D
ACADL Acyl-coenzyme A dehydrogenase, long chain NM_001608 –1.7 D –2.6 D –2 D
CYP3A4 Cytochrome P450, Family 3, subfamily A, polypeptide 4 NM_000776 –2.8 D –6.5 D –7 D
AKR1B10 Aldo-keto reductase family 7, member B10 NM_020299 –3 D –1.4 D –4 D
APR, acute phase response; HBV, hepatitis B virus; PHH, primary human hepatocyte.
aincreased (I), decreased (D), or no change (nc) in gene expression in HBV-infected PHH compared to mock-infected cells.
bPHH prepared from different patients (1-3).
cDue to the dual functions, some of genes are listed twice.
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rather down- than an up-regulation (Table 4), and we did
neither detect IFNa by ELISA (detection limit 47 pg/mL) nor
activation of IRF3 in HBV-infected PHH cultures (Figure 1D).
Thus, HBV up-regulated proteins involved in APR, oxy-
gen detoxiﬁcation, and apoptosis inhibition at the tran-
scriptional and at the protein levels. Moreover, our data
suggest that an IFN response is neither induced by HBV
infection nor by HBV replication in PHHs.
Conﬁrmation of HBV-Induced Changes in
Cellular Gene Expression in HBV-Replicating
Hepatoma Cells, Chronically HBV-Infected
Human Liver Tissue, and HBV-Related HCC
To study whether HBV infection or HBV replication
inﬂuenced gene expression, we compared gene expression
proﬁles of HBV-replicating cell lines HepG2.2.15, established
many years ago21 and HepG2-H1.3, a cell line established in
our laboratory,23,25 with parental HepG2 cells. Total RNA
from these cell lines was examined for the expression of the
cIAP2, TNFAIP8, IER3, IGFBP1, Mn-SOD, CRP, and CYP3A4
genes by real-time RT-PCR.
In contrast to PHH cultures, we found, that hepatoma cell
lines did not express the CRP and CYP3A4 genes at a
detectable level. The expression of the Mn-SOD gene was
unaltered in HBV-replicating cells compared to HepG2 cells.
But, in agreement with our data for HBV-infected PHH cul-
tures, we found that cIAP2 was up-regulated in HepG2.2.15
cells, and TNFAIP8, IER3, and IGFBP1 genes were up-
regulated in both HBV-replicating HepG2-H1.3 and
HepG2.2.15 cells in comparison with parental HepG2 cells
(Table 5).
To determine whether these apoptosis- and
carcinogenesis-related genes were similarly regulated by
HBV in vivo and whether they may be implicated in carci-
nogenesis, we compared the mRNA expression levels
of cIAP2, Mn-SOD, TNFAIP8, IER3, IGFBP1, and CYP3A4
in liver tissue samples from healthy HBV-naive subjects
(n ¼ 11) to those from chronically HBV-infected patients
(n ¼ 11) and patients who had developed HBV-related HCC
(n ¼ 13) (Figure 2).
Real time RT-PCR analysis did not reveal up-regulation
of the IGFBP1 gene (Figure 2). However, in agreement
with our in vitro ﬁndings, we observed an up-regulation of
the cIAP2, Mn-SOD, TNFAIP8, and IER3 genes and down-
regulation of the CYP3A4 gene in HBV-expressing tumor
and, more importantly, in HBV-replicating nontumorous
tissue in comparison to that from healthy donors (Figure 2).
For all genes we observed a signiﬁcant difference in the
expression between HBV-positive nontumorous (HBV) and
HCC tissue (HBV/HCC) and HBV-negative control liver tis-
sue. These results conﬁrmed the primary role of HBV in the
induction of genes encoding for a set of apoptosis inhibitors,
which may contribute to the prevention of apoptosis and to
the transformation of HBV-infected cells.
Activation of STAT3 in HBV-Replicating
Hepatocytes
Next, we investigated the mechanisms underlying up-
regulation of APR- and antiapoptotic- and down-regulation
of pro-apoptotic genes. Since we observed expression
changes of a number of STAT3-regulated genes, namely
cIAP2, Mn-SOD, IER3, IGFBP1, and the numerous APR genes,
we further examined the activation of STAT3 in HBV-
replicating hepatoma cells and PHHs. STAT3 activation
Table 4.Conﬁrmation of Microarray Data by Real-Time
Quantitative Reverse Transcription Polymerase
Chain Reaction
Gene
Fold changea in gene expression: PHHb/HBV
vs PHHb/mock
PHH2 PHH3 PHH4 PHH5
cIAP2 5.1 I 3.9 I 5.1 I 2.9 I
Mn-SOD 3.9 I 2 I 4.1 I 3.4 I
TNFAIP8 2 I 2.3 I 2.3 I 3.1 I
IER3 5.7 I 1.7 I 1.5 I 1.6 I
IGFBP1 116 I 5.3 I 23 I 7.4 I
CRP 18.5 I 115 I 269 I 88 I
CCL2 4 I 21 I 6.7 I 6.9 I
IL-8 24.7 I 10.8 I 8.5 I 4.2 I
APOE 19 D 3.5 D 1.4 D 2.3 D
CYP3A4 4 D 8.6 D 4.3 D 12.2 D
2‘5’OAS nc 2 D nc 1.6 D
IP10 nc 1.7 D 1.5 D 2.5 D
HBV, hepatitis B virus; PHH, primary human hepatocyte.
aIncreased (I) and decreased (D) compared with mock-
infected PHH; mean values of at least 2 independent mea-
surements per experiment are given. nc, no change in gene
expression detected.
bPHH prepared from different patient materials (PHH2–
PHH5).
Table 5.Alteration of Gene Expression in HBV-Replicating
Cell Lines
Gene
Fold changea in gene expression
HepG2-H1.3 vs HepG2 HepG2.2.15 vs HepG2
cIAP2 nc 2.7 ± 0.2 I
TNFAIP8 1.7 ± 0.4 I 2.8 ± 0.5 I
IER3 2 ± 0.1 I 3.5 ± 0.5 I
IGFBP1 3 ± 0.9 I 7.1 ± 0.9 I
Mn-SOD nc nc
CRP nd nd
CYP3A4 nd nd
IL-6 nd nd
NOTE. Mean ± SD values from at least 3 independent
experiments are given.
HBV, hepatitis B virus.
aI, increased; D, decreased compared with HepG2 cells; nc,
no change in gene expression observed; nd, gene expression
was not detectable by real-time quantitative reverse
transcription polymerase chain reaction.
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Figure 2. Changes in cellular gene expression in chronically hepatitis B virus (HBV)–infected human liver tissue and in
HBV-related hepatocellular carcinoma (HCC). Liver tissue samples from healthy HBV-naive subjects (healthy, n ¼ 11), from
chronically HBV-infected patients (HBV, n ¼ 11) and patients who had developed HBV-related HCC (HBV/HCC, n ¼ 13) were
analyzed for expression of the cIAP2, Mn-SOD, IER3, TNFAIP8, CYP3A4, and IGFBP1 genes by real-time reverse transcription
polymerase chain reaction. Each data point represents the expression level determined in a single sample. Mean expression
level ± SD in each group and statistical signiﬁcance (Student’s t test) are given.
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requires phosphorylation of STAT3 at tyrosine 705 (Y705)
which results in STAT3 dimerization and translocation to
the nucleus. We found that levels of phosphorylated STAT3
(pSTAT3) were signiﬁcantly increased in HBV-replicating
hepatoma cells in comparison to HBV-negative cells, as
shown by speciﬁc detection of pSTAT3 by Western blotting
(Figure 3A).
To conﬁrm the activation of the STAT3 signaling
pathway in HBV-replicating cells by an alternative method,
we performed a STAT3-luciferase reporter assay. We
observed a signiﬁcantly higher activity of STAT3-dependent
ﬁreﬂy luciferase in HepG2-H1.3 cells as compared to HepG2
cells (Figure 3C). As in hepatoma cells, STAT3 became
activated in PHHs upon HBV infection (Figure 3D). More-
over, activation of STAT3-signaling increased over the time
parallel to the increased HBV replication as detected by
measuring HBeAg (Figure 3C). A positive correlation be-
tween levels of STAT3 activation and HBV replication was
also observed when HepG2.2.15 and HepG2-H1.3 cells were
compared (Figure 3A and B). Collectively, these data
strongly suggest the involvement of HBV replication in
STAT3 activation.
To test a causal relation between HBV replication and
STAT3 phosphorylation, we studied STAT3 activation in liver
tissue of HBVtg mice16 and mice treated intravenously with
adenoviral vector encoding 1.3-fold overlength genome of
HBV (Ad HBV)19 (Figure 4). For control, age matched wild-
type mice (C57BL/6) or mice treated with control adeno-
viral vector (Ad HBV/ko), respectively, were used. HBVtg
mice displayed a signiﬁcant amount of STAT3 phosphoryla-
tion in hepatocytes around central veins (Figure 4A), where
HBV is primarily replicating,16 while age-matched C57BL/6
mice hardly displayed or completely lacked pSTAT3 in he-
patocytes (Figure 4A). Similarly, Ad HBV–treated mice dis-
played a signiﬁcant amount of pSTAT3-positive hepatocytes
when compared to control (Figure 4B) indicating that HBV
replication activates STAT3 in vivo.
To conﬁrm the relevance of this ﬁnding in the human
situation, we assessed STAT3 phosphorylation and nuclear
translocation in liver needle biopsies of patients with
chronic hepatitis B. We investigated parafﬁn embedded liver
sections of patients with ongoing hepatitis B (n ¼ 11) and
“healthy” control liver biopsies (n ¼ 4) from liver transplant
donors. All liver sections derived from patients with chronic
hepatitis B stained positive for HBV surface antigen and/or
HBV-core protein (data not shown). Immunohistochemical
staining for pSTAT3 revealed that, indeed, in contrast to the
controls, all liver sections from patients with chronic hep-
atitis B showed pSTAT3 phosphorylation in hepatocytes
(Figure 5A). In 7 of 11 HBV-infected patients STAT3 phos-
phorylation and nuclear translocation were mainly detected
in hepatocytes (with 5%–70% of all hepatocytes staining
positive), while in 4 patients pSTAT3 was predominantly
detected in nonparenchymal liver cells (pSTAT3 staining in
1%–15% of all nonparenchymal liver cells) (Figure 5C).
pSTAT3-positive hepatocytes were either evenly distributed
throughout large areas of the liver or occasionally distrib-
uted in a more focal manner, very often neighboring peri-
portal inﬂammatory sites.
To corroborate these data, we analyzed total protein
extracts prepared from tumor- and nontumorous tissue of 3
chronically HBV-infected patients. In contrast to noninfected
liver tissue, phosphorylation of STAT3 was detected in all
analyzed HBV-replicating nontumorous and tumor samples
(Figure 5D). Collectively, our data clearly demonstrate
activation of STAT3 upon HBV infection not only in cell
culture but also in vivo.
IL-6 Dependent and –Independent STAT3
Activation
To understand how STAT3 may become activated by
HBV infection, we ﬁrst measured the concentration of IL-
6—a well-known cytokine inducer of STAT3 signaling—in
HBV-infected PHH cultures prepared from 3 different do-
nors. In all PHH cultures, we observed a pronounced in-
crease in IL-6 concentration after HBV infection (Figure 6A).
As the parental HepG2 cell line does not express IL-639,40
and both HepG2 and HBV-replicating HepG2.2.15 and
HepG2-H1.3 cells expressed the IL-6 gene only at very low
levels below the real time RT-PCR quantiﬁcation limits
(Table 5), we looked for alternative pathways of STAT3
activation in the absence of IL-6. STAT3 signaling can also
be induced by ROS. Indeed, we measured a signiﬁcant in-
crease of ROS in HBV-replicating HepG2.2.15 and HepG2-
H1.3 cells in comparison to parental HepG2 cells
(Figure 6B). In addition, ROS were released after infection of
differentiated HepaRG cells with HBV (Figure 6C). Moreover,
treatment of HepG2-H1.3 with the ROS-inhibitor NAC
reduced STAT3 activity (Figure 6D) indicating that ROS
induced by HBV contribute to activation of STAT3.
Activation of various tyrosine kinases can phosphorylate
STAT3. JAK as well as Src kinase have been shown to acti-
vate STAT3.41 To this end, we detected activation of Src-
kinase by Tyr416 phosphorylation in HBV-replicating
HepG2-H1.3 cells as compared to parental HepG2 cells
(Figure 6E). Thus, our data suggest that HBV replication
activates STAT3 not only in a cytokine-dependent fashion
but also in cytokine-independent by intracellular activation.
Activation of STAT3 Is Needed to Support HBV
Replication and Prevent Apoptosis of HBV
Infected Cells
To examine whether STAT3 activation has any inﬂuence
on HBV infection or on efﬁciency of HBV replication, we
inhibited STAT3 phosphorylation with AG-490, a JAK-2
protein tyrosine kinase inhibitor that inhibits Y705 phos-
phorylation of STAT3.42 AG-490 dissolved in 0.1% of DMSO
was added to HBV-infected HepaRG cells. HBV-infected cells
treated with 0.1% of DMSO only were served as control.
24 hours after AG-490 administration we didn’t detect any
signiﬁcant effect of AG-490 on cell viability at concentra-
tions up to 100 mM (Figure 7A). We therefore used 20 mM
and 100 mM of AG-490 for further experiments. AG490 was
added to mock- or HBV-infected PHHs on day 4 p.i. 24 hours
after AG-490 treatment, cells were either harvested for RNA
and protein isolation or lysed for measurement of caspase
3/7 activity. AG-490 inhibited phosphorylation of STAT3 in
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Figure 3. Activation of signal transducer and activator of transcription 3 (STAT3) in hepatitis B virus (HBV) replicating
cells. (A) Total cellular proteins were analyzed for the presence of tyrosine 705 phosphorylated STAT3 (pSTAT3) and total
STAT3 by Western blotting. One representative Western blot of 3 is shown (left panel). Band density was quantiﬁed using
ImageJ software and relative levels of pSTAT3 were calculated (right panel). Level of pSTAT3 in HepG2 cells was set to
1. Values are shown as mean ± SD (n ¼ 3; ***P < .001; Student’s t test). (B) Secretion of hepatitis B early antigen (HBeAg) into
the medium of stably HBV-replicating HepG2.215 or HepG2-H1.3 cells was determined as signal-to-control (S/CO) ratio,
mean ± SD from 3 independent experiments is given. HepG2 cells were used as negative control. (C) Activation of STAT3 in
HepG2-H1.3 cells was analyzed by the STAT3-luciferase reporter assay. HepG2-H1.3 and HepG2 cells were transfected with
STAT3 Cignal reporter, negative or positive control constructs. Cells were harvested 72 and 96 hours after transfection and
analyzed by the Dual-Luciferase Cignal reporter assay. The activity of STAT3-dependent ﬁreﬂy luciferase is expressed in
relative light units. The activity of constitutively expressed Renilla luciferase was used for internal normalization. Secretion of
HBeAg into the culture medium of HepG2-H1.3 cells is indicated by dots. Values are shown as mean ± SD (n ¼ 3; **P < .01;
***P < .001; Student’s t test). (D) Nuclear proteins extracted from mock- or HBV-infected PHHs prepared from 2 different
donors (PHH4 and PHH5) on day 4 postinfection were analyzed for the presence of pSTAT3 by Western blotting (left panel).
Band densities for pSTAT3 and lamin (loading control for nuclear proteins) were quantiﬁed using ImageJ software (right panel),
and levels of pSTAT3 were calculated relative to respective mock control (set as 1).
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mock- and HBV-infected PHH cells as shown by Western
blotting of nuclear protein preparations (Figure 7B). We
here used expression of lamin as a loading control instead of
total STAT3 because phosphorylated STAT3 drives the
transcription of STAT343 and thus inhibition of STAT3
activation by AG-490 in turn leads to down-regulation of
total STAT3. Purity of nuclear protein preparations was
controlled by Western blotting using anti-albumin anti-
bodies (Figure 7B). Induction of apoptosis in HBV-infected
cells treated with AG-490 was indicated by cleavage of
poly(ADP-ribose) polymerase, which is a well-known sub-
strate of activated caspases44 (Figure 7B). While caspase
activity also increased in AG-490 treated mock-infected
cells, HBV-infected cells showed a markedly higher activa-
tion of effector caspases 3/7 in response to AG-490
(Figure 7C). Since antiapoptotic genes were up-regulated
in HBV-infected hepatocytes and in HBV-expressing tumor
and nontumorous tissue (Figure 1D, Tables 3 and 4 and
Figure 2, respectively), we investigated their expression
level in dependence of STAT3 phosphorylation. Quantitative
real-time RT-PCR analysis of AG-490-treated HBV-infected
PHHs revealed a signiﬁcant down-regulation of cIAP2, Mn-
SOD, IER3 and TNFAIP8 genes (Figure 7D) in comparison
to DMSO-treated, HBV-infected cells. Together, these results
strongly suggest that activation of STAT3 signaling is
important for the prevention of apoptosis and the survival
of HBV-infected cells.
To investigate whether STAT3 activation has an effect on
HBV replication, we determined the expression levels of
HBV pgRNA in HBV-infected PHHs and in HBV-infected
differentiated HepaRG cells treated either with DMSO or
with AG-490 (Figure 8A and C, respectively). Inhibition of
STAT3 in PHHs by 20 mM or 100 mM of AG-490 reduced
relative levels of HBV pgRNA per surviving hepatocyte in a
dose-dependent manner by 54% and 89%, respectively
(Figure 8A). Accordingly, levels of secreted HBeAg dropped
signiﬁcantly after addition of AG-490 (Figure 8B). Similarly,
we observed signiﬁcantly decreased levels of HBV pgRNA
and HBeAg in HBV-infected differentiated HepaRG cells
after treatment with 20 mM or 100 mM of AG-490 (Figure 8C
and D, respectively). To explain a strong decrease in the
level of HBV pgRNA, we quantiﬁed HNF4a, a critical regu-
lator of pgRNA transcription.23,45 We found that HNF4a
expression was strongly dependent on STAT3 activation
(Figure 8A and C) while HNF3a and HNF3b, also playing a
role in regulation of HBV gene expression46–48 remained
unchanged in both cell types (Figure 8A and C). Collectively,
these results suggest that STAT3 regulates transcription
factor HNF4a and in turn activates HBV gene expression
and replication.
Figure 4. Activation of signal transducer and activator of transcription 3 (STAT3) in mouse models of hepatitis B virus
(HBV) infection. (A) Liver tissue samples from HBV transgenic (HBVtg1.3) (n ¼ 5) or age- and sex-matched wild-type C57Bl6
(wild-type) (n ¼ 4) mice were stained for pSTAT3. (B) C57Bl6 mice were transduced with adenoviral vectors either encoding a
replication-competent 1.3-fold overlength genome of HBV (Ad HBV) (n ¼ 3) or one in which all open reading frames were
knocked-out (Ad HBV/ko) (n ¼ 4). Liver tissue samples were isolated on day 7 after transduction and stained for pSTAT3.
Number of pSTAT3-positive hepatocytes per 1000 hepatocytes was calculated from 6 independent tissue sample areas and is
given in the right panels (A, B). For better comparison, ratio determined in wild-type or in Ad HBV k/o mice was set to 1.
Statistical signiﬁcance is shown (Student’s t test).
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To further conﬁrm the results obtained with AG-490, we
knocked down STAT3 by STAT3-speciﬁc siRNA. As primary
hepatocytes are difﬁcult to transfect, we used HBV-
replicating HepG2-H1.3 cells. Transfection of HepG2-H1.3
cells with STAT3-siRNA resulted in w50% reduction in
STAT3 expression at the mRNA and at the protein levels
(Figure 9A) and an w70% decrease of phosphorylated
STAT3. Importantly, siRNA-mediated inhibition of STAT3
signiﬁcantly reduced expression levels of cIAP2, IER3, and
TNFAIP8 genes in HepG2-H-1.3 cells by 37%, 30%, and
50%, respectively (Figure 9B).
To conﬁrm the effects on HBV gene expression and
replication, we examined levels of secreted HBeAg and
transcription of HBV pgRNA. After STAT3 knockdown, both
HBeAg levels and HBV pgRNA levels signiﬁcantly decreased
by 41% and 38%, respectively (Figure 9C and D, respec-
tively). As before, we also observed a strong down-
regulation of HNF4a (by 43%) but not HNF3a or HNF3b
expression upon knockdown of STAT3 (Figure 9D), sug-
gesting that HNF4a links STAT3 activation and HBV
replication.
Taken together, our results strongly suggest that STAT3
serves as a proviral host factor activating HBV transcription
and replication. Since inhibition of STAT3 activation
resulted in induction of apoptosis, down-regulation of
antiapoptotic genes, and a marked decline of HBV gene
expression and replication, we concluded that the activation
of STAT3 is required to prevent apoptosis and to support
HBV persistence and replication.
Discussion
Our study revealed that HBV replication strongly acti-
vates STAT3 signaling in PHHs, infected HepaRG cells,
HBV-replicating hepatoma cells, and mice, as well as in
chronically HBV-infected human liver tissue and in HBV-
related HCC. STAT3 activation led to the up-regulation of
genes encoding for acute phase response proteins and
proteins involved in cell survival. In addition, STAT3 acti-
vation supported HBV replication. Inhibition of JAK-kinases
in HBV-infected PHH cultures prevented STAT3 activation
by phosphorylation and induced apoptosis. Inhibition of
STAT3 phosphorylation as well as STAT3 knockdown by
siRNA led to down-regulation of antiapoptotic genes and
reduction of HBV gene expression and replication. Thus,
STAT3 activation is beneﬁcial for the virus not only by
supporting HBV replication but also by sustaining survival
of HBV replicating hepatocytes.
Figure 5. Phosphorylation and nuclear translocation of signal transducer and activator of transcription 3 (STAT3)
in human livers chronically infected with hepatitis B virus (HBV). (A, B) Immunohistochemical analysis for pSTAT3 and
its subcellular localization in parafﬁn-embedded liver tissue sections of chronically HBV-infected patients and control
individuals. (A) Scale bar: 150 mm. (B) Enlargement, scale bar: 50 mm. The upper row shows nuclear localization of pSTAT3 in
hepatocytes, evenly distributed throughout large areas of the liver as it was detected in most sections. The lower row shows
alternative, more focal distribution of pSTAT3-positive hepatocytes, very often nearby periportal inﬂammatory sites. A peri-
portal inﬂammatory lesion is marked by a dashed line. Arrowheads depict pSTAT3-positive hepatocytes. In some cases,
pSTAT3 and its nuclear localization were detected in hepatocytes (arrowhead) and at the same time in sinusoidal
macrophages (arrows, middle panels). Occasionally, pSTAT3 was predominantly detected in endothelial cells (arrowhead) and
NPCs, most likely Kupffer cells (lower row, right panel). Control livers lack STAT3 phosphorylation and nuclear translocation in
hepatocytes or nonparenchymal liver cells (NPCs) in all liver sections investigated. (C) Quantiﬁcation of pSTAT3-positive cells
relative to total number of hepatocytes or NPCs is shown in percent. Black bars represent hepatocytes, green bars represent
nonparenchymal liver cells. (D) Western blot analysis of total proteins prepared from healthy liver tissue, from chronically
HBV-infected patients or from patients with HBV-related HCC for the presence of pSTAT3. Membranes were reprobed with
anti-STAT3 antibodies to control STAT3 expression levels and protein loading.
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Using genome-wide gene expression proﬁling, we identi-
ﬁed a number of differentially expressed genes in
HBV-infected primary human hepatocyte cultures, and
investigated those genes in stably HBV-producing cell lines as
well as in tumor and nontumorous tissue of patients chron-
ically infected with HBV. We found that most of the regulated
genes are controlled by the STAT3 signaling pathway and
serve to restore cellular homeostasis or oxygen radical
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detoxiﬁcation and favor hepatocyte survival. This suggests a
link to HBV-related cancer development for which STAT3
activation seems important.15,49 Intriguingly, our data
demonstrate that activation of STAT3 is a prerequisite for
efﬁcient HBV replication in HBV-infected hepatocytes.
Microarray analysis revealed only limited differences in
gene expression proﬁles between primary human hepato-
cyte cultures infected with HBV and noninfected controls.
However, hepatocytes obviously responded to HBV infection
by the induction of a STAT3-dependent acute phase
response restoring cell homeostasis and restricting proteo-
lytic activity and tissue damage. The fact that Mn-SOD was
up-regulated and a number of CYP450 family members
were down-regulated, indicated that oxidative stress
contributed to this regulation.
A strong down-regulation of CYP450 enzymes in HBV-
infected hepatocytes detected in our study was similar to
what has been reported in HBVtg mice.50 CYP450 proteins
are mono-oxygenases, which are an important source of
ROS in hepatocytes. Particularly CYP3A4, the predominant
CYP in the liver, was down-regulated in all analyzed PHH
cultures and in HBV-expressing tumor and nontumorous
tissue (Tables 3 and 4 and Figure 2). In our study, antioxi-
dant protein Mn-SOD was up-regulated in all analyzed PHH
cultures, in liver tissue from chronically infected patients
actively replicating HBV as well as in HBV-related HCC
(Figures 1D and 2 and Tables 3 and 4). Mn-SOD, which is
regulated by STAT3, has been reported to be up-regulated
by induction of HBV replication in HepAD38 hepatoma
cells51 and increased in patients with acute viral hepatitis.52
It suppresses oxidative stress damage and ROS-mediated
apoptosis in rat hepatocytes.35 As HBV replication caused
an increase of ROS (Figure 6B–D) and oxidative stress has
been shown to negatively regulate HBV gene expression,53
one could speculate that HBV activates a feedback mecha-
nism: down-regulation of CYP450 enzymes, accompanied by
induction of Mn-SOD and ROS-reducing activity proteins
(IER3)54 will protect the host hepatocyte from oxidative
stress–induced apoptosis and maintain virus replication
despite an activated immune system. As a side effect,
resistance to oxidative stress could provide a selective
growth advantage for preneoplastic hepatocytes, which can
also contribute to HCC development.55
Wieland et al56 found no signiﬁcant change in gene
regulation by microarray analysis of serial liver biopsies of
experimentally infected chimpanzees before the onset of a
T cell response and concluded that HBV is a stealth virus. On
a ﬁrst glance, this appears to be in contrast to our data. A
study by Fisicaro et al57 showed that the innate immune
system is activated from the beginning of HBV infection in
men, indicated by the early development of natural killer
and CD56þ natural killer–T cell responses. In cultured cells,
proinﬂammatory cytokine responses, including IL-6 re-
sponses, are rapidly but transient induced after contact with
HBV. HBV and its antigens even seem to inhibit subsequent
recognition of other patterns.14,58 This indicates that sus-
tained STAT3 signaling, which we observed in the human
tissue samples, requires other triggers in addition to HBV
patterns (eg, inﬂammatory liver disease), which is lacking in
chimpanzees.59
Consistent with the chimpanzee study, our microarray
analyses failed to detect any activation of an IFN response
during HBV replication in the absence of T cells. IRF3 pro-
tein was not activated (Figure 1D) and IFN type I– and type
II–inducible genes 2’5’-oligoadenylatsynthetase and IP10
were rather down-regulated (Table 4)—most likely due to
STAT3 activation which can mitigate virus induced IFN
type I signaling.60
HBV protein expression has been accused to interfere
with IFN type I signaling in infected hepatocytes.61 HBV S62
as well as polymerase proteins63 have been reported to
interfere with host cell-autonomous immune responses
within infected hepatocytes. In particular the HBx
protein,64–66 seems to inﬂuence cellular immune as well as
survival signaling. HBV needs to constantly express HBx,
which is essential to establish and maintain HBV infection67
that otherwise is inhibited by the smc5/6 complex.68 The
virus also requires S as well as polymerase proteins to
produce progeny. Therefore, its replication may well
actively interfere with any interferon response.
As apoptosis is an important mechanism to eliminate
HBV-infected hepatocytes, primes antiviral cytokine re-
sponses in the liver via apoptotic bodies69 and is deleterious
to HBV spread,22 we further analyzed the regulation of
apoptosis-related genes. In all experiments, the balance
between cell survival and cell death was in favor of cell
survival although with some interexperimental variability. A
set of antiapoptotic genes was similarly regulated upon HBV
infection in at least 4 independent PHH cultures infected
with HBV (Table 4) and in stably HBV-replicating cell lines
Figure 6. (See previous page). Activation of signal transducer and activator of transcription 3 (STAT3) by interleukin 6
(IL-6)–dependent and –independent intracellular mechanisms. (A) Secretion of IL-6 into the medium of mock- or HBV-
infected primary human hepatocyte (PHH) cultures prepared from 3 different patients was measured by enzyme-linked
immunosorbent assay (ELISA) on day 4 p.i. Values are shown as mean ± SD (n ¼ 3; ***P < .001; Student’s t test). (B)
Reactive oxygen species (ROS) were determined in HepG2, HepG2.2.15, and HepG2-H1.3 cells on day 7 after reaching
conﬂuency and (C) in mock- or HBV-infected HepaRG cells on day 6 and 10 p.i. by Cellular ROS Detection Assay Kit. Relative
ROS levels in HepG2 cells or in mock-infected HepaRG cells were set to 100%. Values are shown as mean ± SD (n ¼ 6;
*P < .05; **P < .01; Student’s t test). (D) Levels of STAT3 activity after treatment of HepG2-H1.3 cells with 5 mM of ROS-
inhibitor N-acetyl-L-cysteine (NAC) were determined by the STAT3-luciferase reporter assay. Relative activity of ﬁreﬂy lucif-
erase reﬂecting STAT3 activation in HepG2 cells was set to 100%. Values are shown as mean ± SD (n ¼ 6; *P < .05;
***P < .001; Student’s t test). (E) Phosphorylated (Tyr416) and nonphosphorylated Src-kinase were detected by Western blot
analysis using total cellular proteins isolated from HepG2 or HepG2-H1.3 cells. To control HBV replication and protein loading,
membranes were reprobed and stained with anti-HBV core or b actin antibodies, respectively. RLU, relative light units.
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(Table 5). More importantly, we observed an up-regulation
of cIAP2, Mn-SOD, IER3, and TNFAIP8 in HBV-expressing
tumor and nontumorous liver tissue. Of note, our data
strongly suggest a pivotal role of HBV rather than
hepatocarcinogenesis in up-regulation of these anti-
apoptotic genes, since their expression in HBV-expressing
Figure 7. Inhibition of signal transducer and activator of transcription 3 (STAT3) by AG-490 and its consequences on
apoptosis signaling in hepatocytes. (A) Hepatitis B virus (HBV)–infected differentiated HepaRG cells were either treated with
0.1% dimethyl sulfoxide (DMSO) or with different amounts of AG-490 (0.2 mM, 1 mM, 5 mM, 20 mM, and 100 mM); 24 hours after
administration of AG-490, cell viability was analyzed by CellTiter-Blue Cell Viability Assay. Values are given as median ± SD
(n ¼ 3; statistical signiﬁcance relative to DMSO-control; Student’s t test). (B) Mock- or HBV-infected primary human hepa-
tocytes (PHHs) were either incubated with 0.1% DMSO or with 100 mM of AG-490 for 24 hours. Nuclear or cytosolic proteins
were prepared using the NE-PER Nuclear and Cytoplasmic extraction Reagents. Inhibition of STAT3 phosphorylation (upper
panel) was analyzed by Western blotting using nuclear proteins and anti-pSTAT3 antibodies. Purity of nuclear protein prep-
arations was controlled by Western blotting using antialbumin antibodies. Cleavage of poly(ADP-ribose) polymerase (PARP)
(lower panel) was analyzed by Western blotting using nuclear proteins and anti–poly(ADP-ribose) polymerase (PARP) anti-
bodies. Positions of 116 kDa uncleaved (upper band) and 85 kDa cleaved PARP (lower band) are indicated. Membranes were
reprobed with anti-lamin antibodies to control equal protein loading. (C) Caspase 3/7 activity in mock- or HBV-infected PHHs
treated with either DMSO or with 100 mM AG-490 was measured by luminescent caspase 3/7 assay. Mean ± SD is given
(n ¼ 3; ***P < .001; Student’s t test). (D) Expression levels of cIAP2, Mn-SOD, IER3, and TNFAIP8 genes in HBV-infected PHHs
treated with either DMSO or with AG-490 (20 or 100 mM) were determined by real-time reverse transcription polymerase chain
reaction. Gene expression levels in HBV-infected cells treated with DMSO were set to 100%. Values are shown as mean ± SD,
statistical signiﬁcance was calculated relative to the respective DMSO-control sample (n ¼ 3; *P < .05; **P < .01; ***P < .001;
Student’s t test). ns, not signiﬁcant.
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nontumorous liver tissue was signiﬁcantly higher than in
samples from noninfected donors (Figure 2).
A number of signaling pathways are accused to
contribute to hepatocarcinogenesis. Besides NF-kb, and
STAT3 activation,15 the MAPK, Akt/mTOR, WNT/b-catenin,
insulin, and hepatocyte growth factor pathways are regar-
ded to be important in this respect.70 In contrast to previ-
ously published data,71 we did not observe activation of Erk
or JNK by HBV replication in HBV-replicating hepatoma cell
lines (data not shown). The STAT3 pathway, in contrast, was
strongly regulated by HBV replication after infection
of primary human hepatocytes and HepaRG cells or in
HBV-replicating hepatoma cells, and—most importantly—in
all HBV-infected human liver tissue samples. Analysis of
liver needle biopsies from patients with chronic hepatitis B
in comparison with healthy controls in our study conﬁrmed
that HBV infection leads to a predominant STAT3 phos-
phorylation and its nuclear translocation in hepatocytes.
By gene expression analyses of primary human liver cell
cultures infected with HBV, we also detected changes in the
expression of acute phase response genes which are regu-
lated by the IL-6/STAT3 pathway.72,73 STAT3 is activated
via phosphorylation by several tyrosine kinases in response
to various intrinsic and extrinsic factors. Growth factors or a
Figure 8. Inhibition of signal transducer and activator of transcription 3 by AG-490 and its consequences for hepatitis B
virus (HBV) infection. HBV-infected PHHs (A, B) or HepaRG cells (C, D) were treated for 24 hours either with dimethyl
sulfoxide (DMSO) or with AG-490 (20 or 100 mM). (A, C) Expression levels of HBV pregenomic RNA (pgRNA) and HNF4a,
HNF3a, and HNF3b genes were determined by real-time reverse transcription polymerase chain reaction. Gene expression
levels in HBV-infected cells treated with DMSO were set to 100%. (B, D) Levels of hepatitis B early antigen (HBeAg) secreted
into the cell culture medium were determined by as signal-to-control (S/CO) ratio by enzyme-linked immunosorbent assay at
24 hours after treatment with AG-490. All values are shown as mean ± SD, statistical signiﬁcance was calculated relative to the
respective DMSO-control sample (n ¼ 3; *P < .05; **P < .01; ***P < .001; Student’s t test). ns, not signiﬁcant; PHH, primary
human hepatocytes.
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Figure 9. Knockdown of signal transducer and activator of transcription 3 (STAT3) by STAT3-speciﬁc small interfering
(siRNA) and its consequences. (A) Hepatitis B virus (HBV)–replicating HepG2-H1.3 cells were either left untreated or
transfected with 5 nM of STAT3-siRNA or nonsilencing siRNA (nsRNA) as control. STAT3 messenger RNA (mRNA) levels (left
panel) were determined by real-time reverse transcription polymerase chain reaction (RT-PCR). Cells transfected with nsRNA
were set to 100%. Levels of phosphorylated STAT3 (pSTAT3) and STAT3 were examined by Western blot analysis of total
cellular proteins (right panel) using anti-pSTAT3 and anti-STAT3 antibodies, respectively. Membranes were reprobed with
anti–b actin antibodies to control equal protein loading. (B) Gene expression levels of cIAP2, IER3, and TNFAIP8 in HepG2-
H1.3 cells transfected with STAT3 siRNA were determined by real-time RT-PCR relative to those transfected with nsRNA
(set to 100%). (C) Levels of hepatitis B early antigen (HBeAg) secreted into the cell culture medium were determined by the
HBeAg enzyme-linked immunosorbent assay and shown as signal-to-control (S/CO) ratio. (D) Expression levels of pregenomic
RNA (pgRNA) and HNF4a, HNF3a, and HNF3b genes were determined by real-time RT-PCR relative to the respective nsRNA
control. Expression levels in cells transfected with nsRNA were set to 100%. (A–D) Values are shown as median ± SD (n ¼ 3;
**P < .01; ***P < .001; Student’s t test). ns, not signiﬁcant.
358 Hösel et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 3
number of cytokines including IL-6 or IL-10 family members
or leptin activate STAT3. Previously, we demonstrated a
rapid secretion of IL-6 and other NF-kB–dependent cyto-
kines upon contact of nonparenchymal liver cells with
HBV.14 Furthermore, serum levels of IL-6 are signiﬁcantly
higher in hepatitis B patients than in healthy blood donors74
suggesting sustained IL-6 signaling and activation of STAT3
in HBV infection.
However, we and others detected STAT3 activation also
in HBV-replicating hepatoma cell lines75–77 and in HBVtg
mice78 in the absence of cytokine secretion. This requires
additional, cytokine-independent intracellular activation of
STAT3 by HBV replication. Generation of ROS in stably HBV-
producing cell lines HepG2.2.15 and HepG2-H1.3 and upon
infection of HepaRG cells with wild-type HBV (Figure 6), and
oxidative stress may result in STAT3 activation as described
for hepatitis C virus.79 Also, HBx protein might be respon-
sible for intracellular STAT3 activation during HBV repli-
cation,80 as it associates with mitochondria and can cause
oxidative stress by ROS induction51,80,81 as well as may
dysregulate cellular miRNAs such as lethal-782 or
microRNA-21.83 It is very likely, upon HBV replication,
STAT3 is activated by multiple intra- and extracellular
pathways in hepatocytes or in nonparenchymal cells. The
exact contribution of each pathway in activation of STAT3 in
primary hepatocytes is yet to be determined.
Inhibition of STAT3 is known to induce growth arrest
and apoptosis of human HCC cells.63,84 Interestingly, study
performed by Xie et al,77 strongly suggested that some
single nucleotide polymorphisms in STAT3-coding gene
predispose the host with HBV mutations in enhancer or
basal core promoter and precore region or in preS2 start
codon mutations to hepatocarcinogenesis. By chemical in-
hibition of STAT3 phosphorylation and siRNA-mediated
silencing of STAT3, we show that STAT3 activation is
necessary to confer apoptosis resistance in primary human
hepatocytes infected with HBV and in HBV-replicating
HepG2-H1.3 cells. Accordingly, we detected signiﬁcant
down-regulation of cIAP2, Mn-SOD (PHH), IER3, and
TNFAIP8 genes upon inhibition of STAT3 (Figure 7D and
Figure 9B).
Interestingly, inhibition of STAT3 resulted in a marked
decline of HBV gene expression, antigen secretion and
replication (Figure 8, Figure 9C and D). Here, 2 possible
mechanisms may become operative: (1) activated STAT3
may regulate HNF3, and together they bind to the core
domain of HBV enhancer I and positively inﬂuence HBV
gene expression85; alternatively, (2) HNF1,86 an important
transcriptional activator of HNF4a, may up-regulate HNF4a
and thus transcription of pgRNA and HBV replication.23,87
Examining the ﬁrst possible mechanism, we quantiﬁed
expression of HNF3a and HNF3b mRNAs in PHHs and in
HepaRG cells upon inhibition of STAT3 signaling by
administration of AG-490 or speciﬁc STAT3-siRNA. In
neither case, the expression of HNF3a or HNF3b was
changed. In contrast, we found a strong decrease of HNF4a
levels upon inhibition of STAT3 (Figure 8A and C,
Figure 9D). As STAT3 is known to amplify transactivation of
hepatic genes, mediated by HNF1, we speculate that this
mechanism is utilized by HBV to increase transcription of
viral pregenomes, which are the essential template for HBV
replication.
A recent study performed by Huang et al88 demonstrates
that activation of STAT3 by HBV inhibits expression of
micro-RNA miR-204 acting as a tumor suppressor but also
inhibiting HBV pRNA encapsidation and capsid assembly.
Hence, in addition to prevention of apoptosis, attenuation of
oxidative stress, and stimulation of HBV replication through
HNF4a described in our study, activation of STAT3 upon
HBV infection supports HBV replication and malignant
transformation of infected hepatocytes by suppressing miR-
204. Thus, STAT3 signaling acts at various levels in favor of
HBV but also in favor of hepatocyte transformation and
survival.
In summary, our data clearly demonstrate HBV-
mediated activation of STAT3 signaling in different cell
culture systems, in HBV-replicating mice and in HBV-
replicating noncancerous liver and HCC tissue. We found
that HBV activated STAT3 by intra- and extracellular
signaling. Activated STAT3 is crucial to maintain efﬁcient
HBV replication. In addition, STAT3 promotes hepatocyte
survival, essential for virus persistence, but in turn favors
malignant transformation. Hence, inhibition of STAT3 acti-
vation represents a promising target to control HBV infec-
tion and to inhibit HBV-related HCC development.
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